Ba D.M., Ssentongo P., Beelman R.B., Muscat J., Gao X., Richie J.P. Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Advances in Nutrition. 2021;12(5):1691–1704.
Rationale
First meta-analysis asking whether eating mushrooms — not taking extracts — is associated with cancer incidence in human studies.
Methods
Observational studies reporting RR/HR/OR for ≥2 categories of mushroom intake, searched 1966–Oct 2020; random-effects pooling plus nonlinear dose-response. 17 studies: 11 case-control, 6 cohorts.
Results
- Any cancer: pooled RR 0.66 (95% CI 0.55–0.78), n=17.
- Breast cancer: 0.65 (0.52–0.81), n=10; non-breast: 0.80 (0.66–0.97), n=13.
- Significant nonlinear dose-response (P=0.001) — the curve drops steeply at low intake and plateaus: the first weekly serving contributes more than the fifth.
Conclusions
Higher mushroom consumption is associated with lower cancer risk — most robustly breast cancer — consistent with a dietary protective role, pending prospective and interventional confirmation.
Worth noting
This is epidemiology of diet, not therapy: 11/17 studies are case-control, where patients recall diet differently after diagnosis — the 0.66 figure is best read as an upper bound of a possible effect, not proof. The nonlinear plateau is the interesting part: modest regular intake saturates the association, which fits an ergothioneine-type "enough is enough" hypothesis rather than "more is better."